SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)

12 Months Ended

Dec. 31, 2024

Accounting Policies [Abstract]

Schedule of segment reporting

Significant segment expenses and segment net loss were as follows (in thousands):

	Year Ended December 31,
	2024		2023
Research and development
EO-3021 clinical program	$	13,274	$	6,095
Seribantumab clinical program		3,692		10,326
Discovery, preclinical, and other unallocated research and development expense		3,356		1,445
Personnel expenses (including stock-based compensation)		8,275		7,568
General and administrative		16,106		14,904
Restructuring charges		—		5,107
Other segment items(a)		(218)		259
Segment net loss		(44,485)		(45,704)
Reconciliation of segment net loss
Adjustments and reconciling items		—		—
Net loss	$	(44,485)	$	(45,704)
(a) Other segment items in segment net loss includes other income (expense), net and income tax expense.